Skip to content

Newcastle Joint Research Office (NJRO)

Supporting researchers in the development, implementation and delivery of world-class experimental, translational and clinical research.

Menu
  • About
  • New Study
    • Research Proposal
    • Funding
    • Tissue
    • Patient, Carer and Public Involvement (PCPI)
    • Sponsorship and Approvals
    • Data Security
    • Research Passports
  • Active Study
    • Study Progress
    • Recruitment
    • Amendments
    • Audit
    • Closing a Study
  • Resources
    • Documents
    • Training & Guidance
    • FAQ
    • N-RASP
    • Blog
  • Contact
  • News
  • Take Part in Research

RECOVERY trial proves Dexamethasone COVID-19 treatment

Posted on 17th June 202017th June 2020Author NJROCategories COVID-19, Research, Studies

The Oxford University UK RECOVERY trial, of which Newcastle is a site, is the first clinical trial anywhere in the world to show a treatment provides significant impact in reducing patient mortality.

Read the full UK government press release here:

https://www.gov.uk/government/news/world-first-coronavirus-treatment-approved-for-nhs-use-by-government

Post navigation

Previous Previous post: NJRO featured in North East Times Magazine
Next Next post: Working on COVID-19 studies – A day in the life

Recent News

  • IIT Awards – open for applications Monday 30th January 2023 1st February 2023
  • NIHR Research Capability Funding 2023-2024 Call 23rd November 2022
  • Funding Opportunity: Targeting Health Needs & Greenshoots 2023/24 Applications open 13th October 2022
  • IIT Funding Awards 2022/2023 – Applications now open 22nd September 2022
  • Applications open for clinical academic research partnerships (CARP) 7th September 2022
  • Grant Development & Writing Workshop 2nd September 2022

News Archive

Newcastle Joint Research Office
Level 1, Regent Point
Regent Farm Road
Gosforth
Newcastle upon Tyne
NE3 3HD
  • Privacy Policy
  • Accessibility Statement
  • Sitemap

Copyright © 2021 Newcastle Joint Research Office. All rights reserved.

.
  • Twitter